ESMO 2021
T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer
DESTINY-Breast03
ESMO 2021
T-Dxd: New treatment paradigm for patients with…
BEVERLY, WJOG971L
ESMO 2021
VGEF antibody plus TKI: the conundrum continues
Destiny-Breast03
ESMO 2021
T-Dxd - a new standard for 2nd line HER2+ MBC
lung ART
ESMO 2021
PORT: is the discussion really closed?
PRISM, STAR, KEYNOTE-564
ESMO 2021
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
MONALEESA-02:
ESMO 2021
First study to report OS benefit with CDK4/6i in first…
KEYNOTE-716
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of…
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
My ESMO melanoma highlights
POSEIDON
ESMO 2021
Chemoimmunotherapy in 1st line is getting crowded
CheckMate-214
ESMO 2021
Long-term survival with double checkpoint-inhibition
STAMPEDE
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate…
DESTINY-Breast03
ESMO 2021
DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC
KEYNOTE-355
ESMO 2021
KEYNOTE-355: Pembrolizumab A new option for TNBC
MONALEESA-02
ESMO 2021
MONALEESA-2: Long Term 1st Line significant overall…
DESTINY-Breast03
ESMO 2021
T-Dxd: New treatment paradigm for patients with…
MONALEESA-2
ESMO 2021
Ribociclib in 1st line: Long follow-up time confirms OS…
DESTINY-Breast03
ESMO 2021
New standard of care for HER2+ MBC
MONALEESA-2
ESMO 2021
Remarkable improvement of overall survival with…
Monaleesa-02
ESMO 2021
Remarkable survival benefit with Ribociclib defines a…
DESTINY-Breast03
ESMO 2021
T-DXd: Impressive results show the potential of ADC…
KEYNOTE-355
ESMO 2021
Survival data confirm pembrolizumab as standard of care
MONALEESA-02:
ESMO 2021
First study to report OS benefit with CDK4/6i in first…
KEYNOTE-355, DESTINY Breast03, MONALEESA-2
ESMO 2021
MBC significant data: T-Dxd, Pembrolizumab, Ribciclib
DESTINY-Breast03
ESMO 2021
Large step forward in HER2+ MBC with T-Dxd
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
ESMO21 highlights in metastatic and early breast cancer
Carcinomatous Meningitis
ESMO 2021
Management of Carcinomatous Meningitis (CM) in breast…
KEYNOTE355, KEYNOTE-522
ESMO
Two positive trials reinforce the role of…
DESIREE
ESMO 2021
Dose escalation of everolimus in patients with…
KEYNOTE-355
ESMO 2021
Finally a survival benefit in 1st line metastatic TNBC
Destiny-Breast03
ESMO 2021
Impressive new data on the improvement of PFS with…
Destiny-Breast03
ESMO 2021
T-Dxd - a new standard for 2nd line HER2+ MBC
DESTINY-BREAST03, DEBRAH, DESTINY-Breast12, TUXEDO-1
ESMO 2021
Great results and further research
DESTINY-Breast03
ESMO 2021
Becoming the standard of care for patients with HER2+…
KEYNOTE-355
ESMO 2021
A new standard of care for TNBC
MONALEESA-2
ESMO 2021
Ribociclib in 1st line: Lange Nachbeobachtungszeit…
DESTINY-Breast03
ESMO 2021
T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der…
Destiny-Breast03
ESMO 2021
T-DXd: un nuevo estándar de tratamiento en pacientes…
DESTINY-Breast03
ESMO 2021
Krok milowy w leczeniu zaawansowanego, HER2-dodatniego…
KEYNOTE355, KEYNOTE-522
ESMO 2021
Doua trialuri pozitive in tratamentului imunoonologic…
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
Punti salienti nel carcinoma mammario metastatico e…
KEYNOTE-355
ESMO 2021
Nareszcie wydłużenie całkowitego czasu przeżycia w 1.…
Monaleesa-02
ESMO 2021
Beneficiu ramarcabil cu Ribociclib in prima linie de…
Destiny-Breast03
ESMO 2021
Risultati straordinari con il T-DXd in seconda linea…
Destiny-Breast03
ESMO 2021
Dés résultats impressionnants avec les T-DXd en 2ème…
KEYNOTE-522
ESMO 2021
TNBC: CPI performing in the neo-adjuvant setting
BrighTNess
ESMO 2021
TNBC: Carboplatinum in neoadjuvant therapy
HER2+ Meta-Analyses
ESMO 2021
HER2+: Reduced duration of adjuvant Trastuzumab
KEYNOTE-522, BrighTNess
ESMO 2021
TNBC Benefit: Pembro + NACT; Carboplatinum
ESMO 2021
Shortening the trastuzumab therapy to 6 months?
BrighTNess
ESMO 2021
Addition of Carbo-Platin with signifcant EFS advantage
GIM4
ESMO 2021
Extended adjuvant Letrozole with significant DFS…
KEYNOTE-522
ESMO 2021
High risk patients deserve Pembro
BrighTNess
ESMO 2021
Carboplatin, a new standard of care in early TNBC?
coopERA BC
ESMO 2021
Neoadjuvant Giredestrant showed anti-proliverative…
HER2 - Metaanalysen
ESMO 2021
Trastuzumab + Lapatinib; reducing the duration of…
WSG ADAPT TP
ESMO 2021
Patient selection allows efficacy and deescalation
ESMO 2021
ESMO 2021
Verkürzung der Trastuzumab-Therapie auf 6 Monate?
HER2 - Metaanalysen
ESMO 2021
Trastuzumab: Kombination mit Lapatinib und verkürzte…
WSG ADAPT TP
ESMO 2021
Patientenselektion mit hoher Wirksamkeit und…
coopERA BC
ESMO 2021
Giredestrant zeigt anti-proliverative Wirkung im…
KEYNOTE-522
ESMO 2021
Pembrolizumab - eine Option für high risk Pat.
BrighTNess
ESMO 2021
Karboplatyna – nowy standard leczenia we wczesnym,…
BrighTNess
ESMO 2021
Aggiunta di carboplatino neoadiuvante con vantaggio…
GIM4
ESMO 2021
Estensione del letrozolo adiuvante con vantaggio…
BFAST
ESMO 2021
BFAST: The Challenge of new biomarkers for…
DESTINY-Lung01, TROPION, ZENITH20-4
ESMO 2021
Upcoming therapy options in oncogenic-driven NSCLC
EMPOWER-Lung 3, POSEIDON, other
ESMO 2021
IO combinations in advanced NSCLC - revolution and…
LBA47
ESMO 2021
Are vaccines the way forward after progressing on…
Atalante-1, MRTX-500
ESMO 2021
New options for 2nd line after IO-failure
MRTX-500
ESMO 2021
2nd line option after IO failure
BFAST
ESMO 2021
Potential new biomarker for immunotherapy
EMPOWER-Lung3
ESMO 2021
Cemiplimab + chemotherapy: 1st presentation of…
DESTINY-Lung01
ESMO 2021
A new treatment for HER2-mutated NSCLC
POSEIDON
ESMO 2021
Chemoimmunotherapy in 1st line is getting crowded
TROPION-PanTumor01
ESMO 2021
New ADC for lung cancer
ZENITH20-4
ESMO 2021
Poziotinib in HER2 mutated lung cancer
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
New options in salvage setting for EGFR-mutant patients
BEVERLY, WJOG971L
ESMO 2021
VGEF antibody plus TKI: the conundrum continues
DESTINY-Lung01
ESMO 2021
New opportunitiy to treat HER2-mutated lung cancer
WJOG9717L study
ESMO 2021
Failure to demonstrate PFS-improvement when combining…
DESTINY-Lung01
ESMO 2021
Trastuzumab Deruxtecan, a new option for HER2+ lung…
BEVERLY
ESMO 2021
EGFR TKI plus VEGF inhibition
NVALT22
ESMO 2021
KRASG12C and platinum doublet chemotherapy: does the…
EMPOWER-Lung3
ESMO 2021
New 1st line option
ESMO 2021
Gavo-cel dose escalation in refractory…
DESTINY-Lung01, ZENITH20-4
ESMO 2021
HER2 mutations: new opportunities effective
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
Nuevas terapias en linea avanzada de pacientes con…
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären…
POSEIDON
ESMO 2021
Chemoimmuntherapie 1st line: Wohin führt POSEIDON?
DESTINY-Lung01
ESMO 2021
le TdxD, nouvelle option pour les CBNPC HER2+?
ESMO 2021
Kein Vorteil für Anti-IL1 AK
DESTINY-Lung01, ZENITH20-4
ESMO 2021
HER2 Mutation: Drug-Immuno-Conjugates effektiv
Atalante-1, MRTX-500
ESMO 2021
Nuevas opciones terapéuticas en segunda linea tras…
EMPOWER-Lung3
ESMO 2021
Cemilimab + Chemotherapie: Erste Daten der…
DESTINY-Lung01
ESMO 2021
Un nouveau traitement pour le CBNPC HER2-muté
Étude WJOG9717L
ESMO 2021
Absence d'amélioration de la SSP en associant le…
TROPION-PanTumor01
ESMO 2021
Neues AWK beim Lungenkarzinom
IMpower010, IONESCO
ESMO 2021
Immune checkpoint inhibitors - on the way to standard…
COAST, PACIFIC-R
ESMO 2021
Stage III NSCLC - the new stage IV ?!
lung ART
ESMO 2021
PORT: is the discussion really closed?
IMpower010
ESMO 2021
Update on IMpower010
PACIFIC-R
ESMO 2021
Durvalumab consolidation in a real world setting
COAST
ESMO 2021
The power of randomization
IONESCO
ESMO 2021
Endpoint pathological response in induction therapy…
GEMSTONE-301
ESMO 2021
Immunotherapy improves PFS after sequential or…
COAST
ESMO 2021
New option in unresectable NSCLC?
IMpower010
ESMO 2021
Completing the picture
DESTINY-Lung01
ESMO 2021
Potential new standard of care in NSCLC
IONESCO, LCMC3
ESMO 2021
IO mono-Induction: window of opportunity to guide…
COAST
ESMO 2021
COAST on the horizon
GEMSTONE-301
ESMO 2021
Inflection point in next generation drug development
PACIFIC-R, COAST, GEMSTONE-301
ESMO 2021
Update on chemoradiation for stage III NSCLC
IMpower010
ESMO 2021
Wind of change?
IMpower010
ESMO 2021
The benefit of adjuvant atezolizumab in PD-L1 low
Atalante-1
ESMO 2021
Zijn vaccins de toekomst na progressie op…
IMpower010
ESMO 2021
Update IMpower010
PACIFIC-R
ESMO 2021
Quelle efficacité du durvalumab en pratique clinique?
COAST
ESMO 2021
Neue Horizonte durch COAST
NVALT22
ESMO 2021
KRASG12C en platinum doublet chemotherapie: maakt de…
IONECSO
ESMO 2021
Pathological Response als Endpunkt bei…
ESMO 2021
IMpower010 Update: Stellenwert von Atezolizumab…
GEMSTONE-301
ESMO 2021
L'immunothérapie améliore la SSP après une…
lung ART
ESMO 2021
Postoperatie radiotherapie bij N2 ziekte: is de…
IONESCO, LCMC3
ESMO 2021
IO Mono Induktion - Zeitfenster für Immuntherapie
ESMO 2021
Neue IO-Kombinationen vielversprechend
IMpower010
ESMO 2021
Learnings from IMpower010
COAST
ESMO 2021
nouve opzioni per lo NSCLC Stadio III inoperabile?
CASPIAN
ESMO 2021
The tail matters even in ES-SCLC
Checkmate 743, CASPIAN
ESMO 2021
Update on important phase III trials
Checkmate743, CASPIAN
ESMO 2021
Actualizaciones en estudios fase III
CASPIAN
ESMO 2021
la coda conta anche nel SCLC in malattia estesa
NIVOTHYM
ESMO 2021
NIVOTHYM: Immunotherapy for thymic tumors
NIVOTHYM
ESMO 2021
Is there a role for immunotherapy for thymic tumors?
NIVOTHYM
ESMO 2021
Quelle place de l’immunothérapie pour les tumeurs…
Checkmate 743, NCT02856425
ESMO 2021
New era in mesothelioma – stay tuned!
ESMO 2021
Langzeitüberleben durch IO
Checkmate743, CASPIAN
ESMO 2021
Actualizaciones en estudios fase III
CheckMate 744
ESMO 2021
IO-IO, la strada da percorrere nel mesotelioma
KEYNOTE-716
ESMO 2021
KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C
COLUMBUS, SECOMBIT
ESMO 2021
New data for BRAF-mutated melanoma patients
CheckMate 204, GEM1802/EBRAIN-MEL
ESMO 2021
CheckMate 204: Brain metastases - Promising…
RELATIVITY-047
ESMO 2021
RELATIVITY-047: Subgroup updates; Enduring benefit and…
MASTERKEY-265
ESMO 2021
MASTERKEY-265: Pembrolizumab +/- T-VEC
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
My ESMO melanoma highlights
ESMO 2021
Highlights from this year's ESMO
RELATIVITY-047
ESMO 2021
Additional efficacy and shifts in treatment options
KEYNOTE-716
ESMO 2021
New strategies for adjuvant stage II
KEYNOTE-716
ESMO 2021
Pembrolizumab is a good option for adjuvant stage IIB/C
RELATIVITY-047
ESMO 2021
LAG-3-blocking ab shows benefit in combination with…
CheckMate 204
ESMO 2021
Nivo/Ipi for brain metastatses
ESMO 2021
No preference for sequential therapy
COLUMBUS
ESMO 2021
A 5 year update
MASTERKEY-265
ESMO 2021
No significant improvement
RELATIVITY-047
ESMO 2021
Promising data, but some questions remain
KEYNOTE-716
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of…
CheckMate 204
ESMO 2021
T-VEC is not a convincing partner for CPI
COLUMBUS
ESMO 2021
5 year update
KEYNOTE-716
ESMO 2021
First data using immunotherapy as an adjuvant mechanism…
ESMO 2021
Sequencing - start with immunotherapy first
DONIMI
ESMO 2021
Personalized treatment for patients according to IFN-γ…
SECOMBIT
ESMO 2021
ESMO 2021: updates on the SECOMBIT study
ESMO 2021
Keine Präferenz bei sequenzieller Therapie
COLUMBUS
ESMO 2021
5 Jahres Update
KEYNOTE-716
ESMO 2021
Pembro gute Option adjuvant im Stad. IIB/C
KEYNOTE-716
ESMO 2021
Pembro adj. im Stad. II verringert Rezidivrisiko, aber…
CheckMate 204
ESMO 2021
Nivo-Ipi bei Hirnmetastasen
CheckMate 204
ESMO 2021
T-VEC überzeugt nicht als Partner für CPI
SECOMBIT
ESMO 2021
ESMO 2021: aggiornamenti dello studio SECOMBIT
RELATIVITY-047
ESMO 2021
LAG-3-AK zeigt Benefit in Kombi mit Nivo
KEYNOTE-564
ESMO 2021
PRO results support adjuvant IO efficacy, some…
PRISM/CheckMate 214
ESMO 2021
Maintaining the IO-combination with higher flexibility.
PRISM, STAR, KEYNOTE-564
ESMO 2021
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
KEYNOTE-564
ESMO 2021
Quality of Life in adjuvant immunotherapy
PRISM
ESMO 2021
Dual immunotherapy update
PRISM
ESMO 2021
Increased flexibility for side effects due to…
KEYNOTE-564
ESMO 2021
Update adjuvant immunotherapy
ESMO 2021
HIF-2α- a promising target?
CheckMate-214
ESMO 2021
Long-term survival with double checkpoint-inhibition
JAVELIN-renal101
ESMO 2021
Role of cytoreductive nephrectomy in patients treated…
ESMO 2021
HIF-2α - una diana prometedora?
KEYNOTE-564
ESMO 2021
Spannende Daten, wenn auch nicht "game-changing"
PRISM
ESMO 2021
Höhere Flexibilität bei Nebenwirkungen durch Ipilimumab
CheckMate 214
ESMO 2021
Ipi mit festem Stellenwert beim aRCC
ESMO 2021
VESPER: Do we have to intensify perioperative…
ESMO 2021
NABUCCO: IPI matters – discussion on benefits in…
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
ESMO21:The highlights of Bladder cancer
NABUCCO
ESMO 2021
ipilimumab-nivolumab opportunities for alternative…
VESPER
ESMO 2021
Strong signal regarding PFS and OS in ddMVAC
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Improving patients outcome in bladder cancer
NORSE, VESPER
ESMO 2021
ESMO highlights: new combinations FGFRa, Pembro+sEphB4,…
DANUBE
ESMO 2021
PD-L1 as predictor of survival in DANUBE phase III…
IMvigor130, AURA, NABUCCO
ESMO 2021
Deciphering strategies for immunotherapy combinations
VESPER
ESMO 2021
VESPER neoadjuvant chemotherapy phase 3 trial in MIBC
DANUBE
ESMO 2021
PDL-1 como predictor de supervivencia en cáncer de…
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Mejorando el futuro de los pacientes con cáncer de…
NABUCCO
ESMO 2021
Ipilimumab-Nivolumab Möglichkeiten für alternative…
VESPER
ESMO 2021
Starkes Signal bezüglich PFS und OS bei ddMVAC
IMvigor130, AURA, NABUCCO
ESMO 2021
Descifrando las estrategias para mejorar las…
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
Novita’ in tema di tumori vescicali dal congresso ESMO…
ESMO 2021
STAMPEDE: Practice changing in high-risk non-metastatic…
ESMO 2021
ARCHES & PEACE-1: From doublets to triplets in mHSPC?
ESMO 2021
COSMIC-021: mCRPC perspectives in later Lines.
STAMPEDE
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate…
COSMIC-021
ESMO 2021
Hope for patients with mCRPC
PEACE-01
ESMO 2021
Is triplet therapy the new SOC?
ARCHES
ESMO 2021
More data for extending Enzalutamide's label for mHSPC
PRINCE
ESMO 2021
New promising Combination with Pembro and lu-PSMA
PEACE-01
ESMO 2021
Survival benefit with triplet therapy for mHSPC
PEACE-1
ESMO 2021
Chemo Upront: Consider combination with Abiraterone
STAMPEDE
ESMO 2021
STAMPEDE trial: new standard of care for localized high…
VESPER
ESMO 2021
DD-MVAC is the new SOC!
ESMO 2021
Combination therapies and new targeted therapies in…
STAMPEDE
ESMO 2021
Significant advances in M0 PCa
PEACE-01
ESMO 2021
Practice changing results for mHSCP
STAMPEDE
ESMO 2021
Triplet or duplet for high-risk patients
PEACE-1, ARCHES
ESMO 2021
mHSPC: ADT alone is not enough!
PEACE-01
ESMO 2021
PEACE-1 phase 3 trial in metastatic CSPC
PEACE-01
ESMO 2021
Is it really practice changing?
ESMO 2021
PSMA – RLT is here!
ARCHES
ESMO 2021
Enzalutamide added to ADT shows clear survival benefit…
STAMPEDE
ESMO 2021
New data change our practice in non-metastatic…
DS-7300
ESMO 2021
DS7300 - an exciting novel therapy in prostate cancer…
STAMPEDE
ESMO 2021
Resultat från STAMPEDE öppnar för ny…
STAMPEDE
ESMO 2021
Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην…
ARCHES
ESMO 2021
Ein weiteres Puzzlestück für Zulassungserweiterung von…
ESMO 2021
Kombinationsbehandlingar och nya riktade terapier vid…
PRiNCE
ESMO 2021
Neue vielversprechende Kombination mit Pembro und…
COSMIC-021
ESMO 2021
Hoffnung für Patienten mit mCRPC
ARCHES
ESMO 2021
Längre uppföljningstid I ARCHES-studien visar klar…
STAMPEDE
ESMO 2021
Triplet oder Duplette beim hochrisiko Patienten
PEACE-1
ESMO 2021
Chemo Upfront: Kombination mit Abiraterone bedenken!
PEACE-1
ESMO 2021
PEACE-1 studien visar överlevnadsvinst med trippel…
PEACE-1, ARCHES
ESMO 2021
Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η…
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären…
ESMO 2021
Covid19 & Cancer: updates from ESMO 2021
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!